BCAL DIAGNOSTICS LIMITED - Announcements

Market Cap $27.75M Add to my watchlist

Healthcare Biotechnology

BCAL Diagnostics Limited is an Australia-based biotechnology company, which is focused on... BCAL Diagnostics Limited is an Australia-based biotechnology company, which is focused on improving health outcomes for women. The Company’s principal activities include the development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer, including preparation for clinical trials. It developed a blood screening test to be used alongside breast cancer screening methods. The technology initially complements imaging technologies, such as the mammogram, while it further progresses the development of a monitoring and screening test suitable for women of all ages and backgrounds in any location. Its BCAL test is a lipid biomarker blood (Breast Cancer Associated Lipids test) test with the potential to be used for breast cancer prevention, screening, and monitoring. The Company has partnered with Precion Inc. to optimize protocols and procedures for the clinical studies required for regulatory approvals across several jurisdictions.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

BDX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/04/24	521.59KB	Share
BDX	Appointment of Strategic CEO to Lead Commercial Launch	PRICE SENSITIVE	06/03/24	217.93KB	Share
BDX	Half Yearly Report and Accounts	PRICE SENSITIVE	20/02/24	668.63KB	Share
BDX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/24	521.5KB	Share
BDX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/23	376.8KB	Share
BDX	Preliminary Final Report	PRICE SENSITIVE	30/08/23	505.25KB	Share
BDX	Share Purchase Plan Offer Booklet	PRICE SENSITIVE	30/08/23	352.6KB	Share
BDX	$2.4m Capital Raise to Further BREASTEST Commercialisation	PRICE SENSITIVE	28/08/23	169.6KB	Share
BDX	Trading Halt	PRICE SENSITIVE	24/08/23	254.54KB	Share
BDX	Breakthrough Results a Major Step Towards Commercialisation	PRICE SENSITIVE	02/08/23	193.16KB	Share
BDX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/07/23	387.47KB	Share
BDX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/04/23	219.05KB	Share
BDX	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/23	557.69KB	Share
BDX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	16/01/23	116.54KB	Share
BDX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	135.99KB	Share
BDX	Preliminary Final Report	PRICE SENSITIVE	30/08/22	380.59KB	Share
BDX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/22	111.26KB	Share
BDX	BCAL Enters US Product Development Agreement with Precion	PRICE SENSITIVE	28/06/22	50.05KB	Share
BDX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/22	189.47KB	Share
BDX	Appendix 4D & Interim Report	PRICE SENSITIVE	18/02/22	830.8KB	Share
BDX	7 February Announcement - Additional Information	PRICE SENSITIVE	08/02/22	103.11KB	Share
BDX	Recent Analysis Significantly Improves Commercial Prospects	PRICE SENSITIVE	07/02/22	48.81KB	Share
BDX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/01/22	113.43KB	Share
BDX	Dr John Hurrell Appointed Chief Executive Officer	PRICE SENSITIVE	11/01/22	50.17KB	Share
BDX	Strong Cohort 4 Testing Data Demonstrates Value of BCAL Test	PRICE SENSITIVE	03/11/21	185.43KB	Share
BDX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/21	233.3KB	Share
BDX	Australian Clinical Studies Launched	PRICE SENSITIVE	03/09/21	137.38KB	Share
BDX	Preliminary Final Report	PRICE SENSITIVE	31/08/21	463.84KB	Share
BDX	Market Update	PRICE SENSITIVE	17/08/21	167.62KB	Share

BDX Quarterly Activities/Appendix 4C Cash Flow Report
26/04/24	PRICE SENSITIVE	521.59KB	Share
BDX Appointment of Strategic CEO to Lead Commercial Launch
06/03/24	PRICE SENSITIVE	217.93KB	Share
BDX Half Yearly Report and Accounts
20/02/24	PRICE SENSITIVE	668.63KB	Share
BDX Quarterly Activities/Appendix 4C Cash Flow Report
30/01/24	PRICE SENSITIVE	521.5KB	Share
BDX Quarterly Activities/Appendix 4C Cash Flow Report
31/10/23	PRICE SENSITIVE	376.8KB	Share
BDX Preliminary Final Report
30/08/23	PRICE SENSITIVE	505.25KB	Share
BDX Share Purchase Plan Offer Booklet
30/08/23	PRICE SENSITIVE	352.6KB	Share
BDX $2.4m Capital Raise to Further BREASTEST Commercialisation
28/08/23	PRICE SENSITIVE	169.6KB	Share
BDX Trading Halt
24/08/23	PRICE SENSITIVE	254.54KB	Share
BDX Breakthrough Results a Major Step Towards Commercialisation
02/08/23	PRICE SENSITIVE	193.16KB	Share
BDX Quarterly Activities/Appendix 4C Cash Flow Report
27/07/23	PRICE SENSITIVE	387.47KB	Share
BDX Quarterly Activities/Appendix 4C Cash Flow Report
24/04/23	PRICE SENSITIVE	219.05KB	Share
BDX Half Yearly Report and Accounts
23/02/23	PRICE SENSITIVE	557.69KB	Share
BDX Quarterly Activities/Appendix 4C Cash Flow Report
16/01/23	PRICE SENSITIVE	116.54KB	Share
BDX Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	135.99KB	Share
BDX Preliminary Final Report
30/08/22	PRICE SENSITIVE	380.59KB	Share
BDX Quarterly Activities/Appendix 4C Cash Flow Report
28/07/22	PRICE SENSITIVE	111.26KB	Share
BDX BCAL Enters US Product Development Agreement with Precion
28/06/22	PRICE SENSITIVE	50.05KB	Share
BDX Quarterly Activities/Appendix 4C Cash Flow Report
28/04/22	PRICE SENSITIVE	189.47KB	Share
BDX Appendix 4D & Interim Report
18/02/22	PRICE SENSITIVE	830.8KB	Share
BDX 7 February Announcement - Additional Information
08/02/22	PRICE SENSITIVE	103.11KB	Share
BDX Recent Analysis Significantly Improves Commercial Prospects
07/02/22	PRICE SENSITIVE	48.81KB	Share
BDX Quarterly Activities/Appendix 4C Cash Flow Report
27/01/22	PRICE SENSITIVE	113.43KB	Share
BDX Dr John Hurrell Appointed Chief Executive Officer
11/01/22	PRICE SENSITIVE	50.17KB	Share
BDX Strong Cohort 4 Testing Data Demonstrates Value of BCAL Test
03/11/21	PRICE SENSITIVE	185.43KB	Share
BDX Quarterly Activities/Appendix 4C Cash Flow Report
28/10/21	PRICE SENSITIVE	233.3KB	Share
BDX Australian Clinical Studies Launched
03/09/21	PRICE SENSITIVE	137.38KB	Share
BDX Preliminary Final Report
31/08/21	PRICE SENSITIVE	463.84KB	Share
BDX Market Update
17/08/21	PRICE SENSITIVE	167.62KB	Share

REFRESH

(20min delay)
Last 11.0¢		Change -0.005(4.35%)		Mkt cap ! $27.75M

Open	High	Low	Value	Volume
11.0¢	11.0¢	11.0¢	$7.843K	71.29K

Buyers (Bids)

No.	Vol.	Price($)
3	36514	10.5¢

Sellers (Offers)

Price($)	Vol.	No.
11.0¢	20000	1

View Market Depth

No.	Vol.	Price($)
3	36514	0.105
3	106000	0.100
1	100000	0.098
1	100000	0.092
2	566693	0.091

Price($)	Vol.	No.
0.115	104770	1
0.120	63332	1
0.125	100000	1
0.130	136123	2
0.140	40076	1

Last trade - 11.00am 24/05/2024 (20 minute delay)


Last 11.5¢		Change -0.005 ( 4.55 %)
Open	High	Low	Volume
10.5¢	11.5¢	10.5¢	17649
Last updated 11.27am 24/05/2024 ?

BDX (ASX) Chart

BCAL DIAGNOSTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available